[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Wuxi Hisky Medical Technology Co Ltd\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":64},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,39],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100577779","livq-box-parameters-in-the-diagnosis-of-liver-inflammation-100577779",false,"NCT06802731","LivQ-box® Parameters in the Diagnosis of Liver Inflammation","A Multicenter Study on the Application of LivQ-box® Parameters in the Diagnosis of Liver Inflammation in Patients with Non-alcoholic Fatty Liver Disease","Inclusion Criteria:\n\n* Patients diagnosed with NAFLD according to The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases;\n* Age over 18 years old, gender not limited;\n* Not combined with liver diseases (such as viral hepatitis, drug-induced liver injury, autoimmune liver disease);\n* Perform iLivTouch examination within ± 14 days of liver pathology examination;\n* No history of excessive alcohol consumption (converted to ethanol:\\\u003C140g\u002Fweek for males,\\\u003C70g\u002Fweek for females);","ALL","18 Years",{"count":19,"type":20},365,"ESTIMATED","OBSERVATIONAL","To evaluate the correlation between LivQ-box® parameters carried by iLivTouch and liver inflammation in patients with NAFLD, as well as the diagnostic value of liver inflammation of different severity levels.",[24,25],"Liver Inflammation","Fatty Liver Disease","RECRUITING","2025-01-24",{"date":29,"type":30},"2025-01-31","ACTUAL",{"date":32,"type":30},"2024-01-01",{"date":34,"type":20},"2025-06-30",{"name":36,"class":37},"Wuxi Hisky Medical Technology Co Ltd","INDUSTRY",1,{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":46,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":48,"conditions":49,"keywords":52,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":38},"100485179","prevalence-of-mafld-in-patients-with-type-2-diabetes-in-jiangsu-province-of-china-100485179","NCT05597709","Prevalence of MAFLD in Patients With Type 2 Diabetes in Jiangsu Province of China","Prevalence of Metabolic Associated Fatty Liver Disease in Patients With Type 2 Diabetes in Jiangsu Province of China: a Prospective, Multicenter, Real-world Study","Inclusion Criteria:\n\n* Diagnosed as T2DM according to the Chinese Guidelines for the Prevention and Treatment of Type 2 Diabetes\n* UAP were measured based on iLivTouch\n* Willing to attend this study and able to provide the written informed consent.\n\nExclusion Criteria:\n\n* Other types of diabetes\n* Patients unable to receive regular follow-up",{"count":47,"type":20},2900,"In 2019, the number of patients with diabetes was about 463 million in the world, accounting for 8.3% of the total population, and it is expected to rise to 578 million (9.2%) by 2030 and 700 million (9.6%) by 2045. According to the WHO diagnostic criteria, the prevalence of diabetes among adults in China from 2015 to 2017 was 11.2%, of which over 90% were type 2 diabetes mellitus (T2DM). The global prevalence of non-alcoholic fatty liver disease (NAFLD) is also very high, which was approximately 25% in 2016. The prevalence of NAFLD may continue to rise. NAFLD is often accompanied by clinical manifestations of metabolic syndrome, such as obesity, T2DM, hyperlipidemia and hypertension.",[50,51],"Type 2 Diabetes Mellitus in Remission","Metabolic Associated Fatty Liver Disease",[53,54,55],"Type 2 diabetes mellitus","Metabolic associated fatty liver disease","ultrasound attenuation parameter","2022-10-24",{"date":58,"type":30},"2022-10-28",{"date":60,"type":30},"2022-07-01",{"date":62,"type":20},"2027-06-01",{"name":36,"class":37},""]